
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated a robust performance in the transcatheter aortic valve replacement (TAVR) market, with a 10.6% year-over-year revenue growth, comfortably surpassing consensus estimates. The company’s transcatheter mitral and tricuspid technologies (TMTT) have shown exceptional growth, with a 48.3% increase in sales, reflecting strong adoption rates of their innovative products. Management's increased confidence in achieving its 2026 sales guidance of 8-10% year-over-year growth underlines the company's solid market position and growth potential in the expanding global market for structural heart devices.
Bears say
Edwards Lifesciences's financial outlook appears negative due to a significant miss in adjusted operating margin, attributed primarily to increased selling, general, and administrative expenses that exceeded expectations. Despite reporting strong sales in certain segments such as transcatheter aortic valves, the overall organic growth was underwhelming, leading to earnings per share that fell short of consensus estimates. Furthermore, the company faces numerous risks, including potential market share loss due to emerging competition, slower-than-anticipated growth in key markets, and challenges related to product adoption and clinical trial outcomes, which could hinder its long-term growth trajectory.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares